RT info:eu-repo/semantics/article
T1 The ellagic acid derivative 4,4′-Di-O-methylellagic acid efficiently inhibits colon cancer cell growth through a mechanism involving WNT16
A1 Ramírez de Molina, Ana
A1 Vargas, Teodoro
A1 Molina, Susana
A1 Sánchez, Jenifer
A1 Martínez Romero, Jorge
A1 González-Vallinas Garrachón, Margarita
A1 Martín Hernández, Roberto
A1 Sánchez Martínez, Ruth
A1 Gómez de Cedrón, Marta
A1 Dávalos, Alberto
A1 Calani, Luna
A1 Rio, Daniele del
A1 González Sarrías, Antonio
A1 Espín, Juan Carlos
A1 Tomás Barberán, Francisco A.
A1 Reglero, Guillermo
K1 Cáncer
K1 Ácido elágico
K1 3207.13 Oncología
AB Ellagic acid (EA) and some derivatives have been reported to inhibit cancer cell proliferation, induce cell cycle arrest, and modulate some important cellular processes related to cancer. This study aimed to identify possible structure-activity relationships of EA and some in vivo derivatives in their antiproliferative effect on both human colon cancer and normal cells, and to compare this activity with that of other polyphenols. Our results showed that 4,4′-di-O-methylellagic acid (4,4′-DiOMEA) was the most effective compound in the inhibition of colon cancer cell proliferation. 4,4′-DiOMEA was 13-fold more effective than other compounds of the same family. In addition, 4,4′-DiOMEA was very active against colon cancer cells resistant to the chemotherapeutic agent 5-fluoracil, whereas no effect was observed in nonmalignant colon cells. Moreover, no correlation between antiproliferative and antioxidant activities was found, further supporting that structure differences might result in dissimilar molecular targets involved in their differential effects. Finally, microarray analysis revealed that 4,4′-DiOMEA modulated Wnt signaling, which might be involved in the potential antitumor action of this compound. Our results suggest that structural-activity differences between EA and 4,4′-DiOMEA might constitute the basis for a new strategy in anticancer drug discovery based on these chemical modifications.
PB American Society for Pharmacology and Experimental Therapeutics (ASPET)
SN 0022-3565
YR 2015
FD 2015
LK http://uvadoc.uva.es/handle/10324/42587
UL http://uvadoc.uva.es/handle/10324/42587
LA eng
NO Journal of Pharmacology and Experimental Therapeutics, 2015, vol. 353, n. 2, p. 433-444
NO Producción Científica
DS UVaDOC
RD 25-abr-2024